# Dance-based avenues to advance nonpharmacologic treatment of chemotherapy effects (DAANCE): Study protocol for a multi-center, randomized controlled trial

## TL;DR

This study tests if dance can help breast cancer survivors manage chemotherapy-related nerve pain and balance issues better than standard care.

## Contribution

Evaluates Adapted Argentine Tango as a nonpharmacologic treatment for chemotherapy-induced neuropathy in breast cancer survivors.

## Key findings

- Assesses Tango's impact on sensation, function, and biomarkers in breast cancer survivors with neuropathy.
- Compares Tango to standard care using patient-reported outcomes and clinical measures over 4 weeks.
- Explores potential mechanisms like postural control and cognitive load as outcomes.

## Abstract

Breast cancer (BC) is among the most common forms of cancer, particularly among women. Chemotherapies that are most effective in treating BC are known to cause chemotherapy-induced neuropathy (CIN), thus leaving survivors with sensory deficits including pain, numbness, and tingling in the extremities; functional deficits such as impaired neuromotor control and motor-cognitive integration; reduced quality of life; and increased fall risk. Current pharmacologic treatments show limited efficacy and create additional unwanted side effects. In contrast, physical activity (PA) has emerged as a promising nonpharmacologic candidate for managing CIN symptoms. The purpose of this trial is to evaluate the effect of Adapted Argentine Tango (Tango) as a potential treatment for CIN. Toward this end, we will assess the intervention effect of Tango vs. the standard of care (SOC) on patient-reported outcomes of sensation, clinically-relevant measures of function, and potential mechanisms of action. We hypothesize that 4 weeks of Tango practice will improve sensation and function more than SOC among BC survivors with CIN and demonstrated balance dysfunction.

In a multi-center, prospective, randomized controlled clinical trial, participants are randomly assigned (1:1 ratio) to the Tango experimental or the SOC active control arms. Primary outcomes are measured from baseline to after 4 weeks of intervention in patient-reported outcomes (PROs) of sensation and dual-task function. Secondary outcomes include additional PROs, such as fatigue, and clinical measures of interest after 4 and 8 weeks of intervention and 1 month following intervention completion. Exploratory measures include postural control, gait stability, cognitive load, and blood-based biomarker concentrations. Linear mixed models will be used to model changes in PROs and function. The primary estimand will be the difference in mean change in primary outcomes from baseline to week 4 between treatment groups.

The scientific premise of this study is that Tango stands to improve CIN symptoms significantly more than the current standard of care by combining PA with auditory-motor entrainment and social engagement. Our findings may lead to a safe non-pharmacologic intervention that improves CIN-related deficits.

This trial was first posted on 12/27/24 at ClinicalTrials.gov under the identifier NCT06749210.